NCT07667556 The Combined Effect of Mulligan Mobilization, Pain Neuroscience-Based Training, and Core Stabilization Exercises in Frozen Shoulder Patients
| NCT ID | NCT07667556 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yeditepe University |
| Condition | Frozen Shoulder |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-04-21 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2026-04-21 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this randomized controlled study is to investigate the effects of a combined rehabilitation program consisting of Mulligan Mobilization with Movement (MWM), Pain Neuroscience Education (PNE), and core stabilization exercises in individuals with adhesive capsulitis (frozen shoulder). The main questions this study aims to answer are: Does the combination of Mulligan mobilization, Pain Neuroscience Education, and core stabilization exercises reduce pain in individuals with adhesive capsulitis? Does this combined intervention improve shoulder range of motion, shoulder function, quality of life, scapular dyskinesis, and pain catastrophizing compared with conventional physical therapy? Participants diagnosed with adhesive capsulitis will be randomly assigned to one of two groups. The intervention group will receive Mulligan mobilization, Pain Neuroscience Education, and core stabilization exercises, while the control group will receive conventional physical therapy, including TENS, hot-pack application, passive joint mobilization, and stretching exercises. Both groups will participate in treatment sessions three times per week for six weeks. Outcome measures will be assessed at baseline and after completion of the 6-week intervention period.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years * Diagnosis of adhesive capsulitis confirmed by an orthopedic surgeon or a physical medicine and rehabilitation physician * Presence of shoulder pain and limitation of shoulder range of motion * Ability to communicate verbally * Ability to understand study procedures and educational content * Willingness to participate and provide written informed consent * Mini-Mental State Examination (MMSE) score of 24 or higher * Ability to attend treatment and assessment sessions regularly Exclusion Criteria: * MMSE score below 24 * Severe cognitive impairment * Severe psychiatric disorders * Active infectious disease * Active malignancy * Uncontrolled cardiovascular disease * Presence of a cardiac pacemaker * Contraindications to transcutaneous electrical nerve stimulation (TENS) * Neurological disorders that may affect participation or outcomes * Systemic diseases that may interfere with the safe implementation of the intervention * Inability to comply with the study protocol or attend scheduled sessions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07667556 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Frozen Shoulder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07667556 currently recruiting?
Yes, NCT07667556 is actively recruiting participants. Contact the research team at dilay.doner@std.yeditepe.edu.tr for enrollment information.
Where is the NCT07667556 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07667556 clinical trial?
NCT07667556 is sponsored by Yeditepe University. The trial plans to enroll 36 participants.